PSCA and pachyonychia congenita: The efficacy of anticancer vaccines of PC can be analyzed using its specific biological markers or features, which include an early diagnosis of disease recurrences, slow growth, and a series of TAAs (PSA, and PSMA), TSAs [168], prostate stem cell antigen (PSCA), prostate acid phosphatase (PAP), PCA-3 antigen, six-transmembrane epithelial antigens of prostate (STEAP), and mucin-1 [169].